Paul Dano is set to star opposite Callum Turner and Margaret Qualley in Paramount's remake of the 1981 supernatural thriller Possession, Deadline can confirm. The project is being built around a straightforward decision: put marquee acting weight in front of a recognizable genre title, then let the modern horror playbook do the rest.

Character details are currently under wraps, but the creative through-line is not. Parker Finn, the writer-director behind the hit horror franchise Smile, announced his take on Possession for Paramount in 2024, and he is directing from his own script. That pairing matters because Finn is not being brought in as a “director for hire.” He is directing his own writing, which typically signals creative control, faster feedback loops, and fewer pivots after the first production drafts hit the room.

For executives, remakes like this are more than a nostalgia checkbox. Studios lean into recognizable properties because horror, in particular, can be both scalable and repeatable at the brand level. A title like Possession comes with built-in audience recognition and established genre expectations: supernatural dread, escalating threat, and an emotionally sticky central conflict. But the risk is also baked in. If the new version feels like it is only chasing vibes from the original, it can underperform with genre fans who notice when a film is playing defense.

Finn’s involvement is a partial antidote to that risk. Smile’s success (the source calls it a “hit horror franchise”) gives Paramount a reason to believe the creative tone will land with contemporary horror audiences, not just classic-thriller diehards. The industry has increasingly treated horror as a discipline where writing and direction are tightly coupled to audience impact, whether that audience is coming for scares, craft, or the kind of tightly controlled character tension that keeps people talking after the credits.

Then there is the cast strategy. Deadline’s report stacks Paul Dano, Callum Turner, and Margaret Qualley as the core trio, even though their character details are under wraps. Strategically, this is the kind of casting that signals intent to blend mainstream draw with genre credibility. Dano brings prestige and intensity; Turner has an action-adjacent, screen presence profile that can broaden appeal; and Qualley is a current-generation name that travels well across audiences. When character details are withheld early, it also gives the studio room to market without locking itself into a single interpretation too early. In practical terms: less risk of mismatch between trailer expectations and the actual screenplay.

From a development standpoint, the “director from his own script” line matters for production planning and board-level confidence. Boards and senior leadership tend to like projects where the creative voice is accountable within a single pipeline, because it reduces the number of handoffs that can create drift. It also helps with budgeting conversations. When you control the writing, you can usually defend creative decisions with clarity in early cost reviews, especially for a supernatural thriller where practical effects, production design, and shoot complexity can swing quickly.

Regulatory and compliance considerations rarely make headlines for film development, but they exist in the background. In the US, content ratings are a commercial variable, not just a legal formality. Horror projects can trigger scrutiny based on violence, disturbing content, and thematic elements. While the source does not provide any plot specifics, holding character details “under wraps” often means the creative team has not locked down the final narrative mechanics yet. That gives Paramount time to calibrate what gets shown, what gets implied, and how the story plays at the level that rating boards and distribution partners will expect. It is not about sanitizing a horror story. It is about ensuring the film can travel.

Second-order implications for executives at peer studios are pretty clear. If Paramount moves fast on a remake with a current horror auteur attached, it can tighten competitive timelines for other “genre IP revival” projects. Studios often track not only who is attached, but also who has creative control and how clearly the project is already positioned as more than a rights exercise. The message is: the market is open for horror remakes that feel authored, not assembled.

Ultimately, this is a bet on conversion. Paramount is betting that a classic 1981 supernatural thriller, reinterpreted through Parker Finn’s Smile success logic, can translate to today’s audience using a cast built for both attention and screen intensity. If they get the tone right, the project could become the next recognizable horror franchise entry in a lineup that studios increasingly treat like repeatable revenue engines, not one-offs. And if they do not, the remake category has little patience for mediocrity, because the audience can always point back to what the original did and what it still remembers.